Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Terui T, et al. Among authors: tada y. Am J Clin Dermatol. 2024 Jan;25(1):165-167. doi: 10.1007/s40257-023-00825-0. Am J Clin Dermatol. 2024. PMID: 38060175 Free PMC article. No abstract available.
Safety of biologics in psoriasis.
Kamata M, Tada Y. Kamata M, et al. Among authors: tada y. J Dermatol. 2018 Mar;45(3):279-286. doi: 10.1111/1346-8138.14096. Epub 2017 Dec 10. J Dermatol. 2018. PMID: 29226369 Review.
Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S, Kanai Y, Murotani K, Nomura T, Ito K, Ohata C, Yamazaki F, Miyagi T, Takahashi H, Okubo Y, Saeki H, Honma M, Tada Y, Mabuchi T, Higashiyama M, Kobayashi S, Hashimoto Y, Seishima M, Kakuma T. Imafuku S, et al. Among authors: tada y. J Dermatol Sci. 2021 Mar;101(3):185-193. doi: 10.1016/j.jdermsci.2021.01.002. Epub 2021 Jan 7. J Dermatol Sci. 2021. PMID: 33495058 Free article. Clinical Trial.
Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, Tada Y, Nemoto O, Rozzo SJ, Kawamura M, Ohtsuki M. Imafuku S, et al. Among authors: tada y. J Dermatol. 2021 Jun;48(6):844-852. doi: 10.1111/1346-8138.15763. Epub 2021 Feb 1. J Dermatol. 2021. PMID: 33523513 Free PMC article. Clinical Trial.
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn AM, Kawamura M, Ohtsuki M. Igarashi A, et al. Among authors: tada y. J Dermatol. 2021 Jun;48(6):853-863. doi: 10.1111/1346-8138.15789. Epub 2021 Feb 25. J Dermatol. 2021. PMID: 33630387 Free PMC article. Clinical Trial.
1,633 results